APA (7th ed.) Citation

G, C., AJ, A., E, S., C, O., A, H., J, R., . . . C, P. (2024). Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): Interim analysis of a multicentre, open-label, randomised, phase 3 trial. The Lancet. Haematology, 11(11), e816. https://doi.org/10.1016/S2352-3026(24)00249-7

Chicago Style (17th ed.) Citation

G, Cook, et al. "Ixazomib as Consolidation and Maintenance Versus Observation in Patients with Relapsed Multiple Myeloma Eligible for Salvage Autologous Stem-cell Transplantation (Myeloma XII [ACCoRD]): Interim Analysis of a Multicentre, Open-label, Randomised, Phase 3 Trial." The Lancet. Haematology 11, no. 11 (2024): e816. https://doi.org/10.1016/S2352-3026(24)00249-7.

MLA (9th ed.) Citation

G, Cook, et al. "Ixazomib as Consolidation and Maintenance Versus Observation in Patients with Relapsed Multiple Myeloma Eligible for Salvage Autologous Stem-cell Transplantation (Myeloma XII [ACCoRD]): Interim Analysis of a Multicentre, Open-label, Randomised, Phase 3 Trial." The Lancet. Haematology, vol. 11, no. 11, 2024, p. e816, https://doi.org/10.1016/S2352-3026(24)00249-7.